EMA’s human medicines committee, CHMP , has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come back after at least two platinum-based chemotherapies and who cannot have further platinum-based therapy. The recommendation follows the review of final data from the ARIEL4 study, 1 which compared Rubraca with chemotherapy in patie...